Ilika’s Graeme Purdy talks Cirtec partnership, P1 Cells milestone and further grant support (LON:IKA)

Ilika plc
[shareaholic app="share_buttons" id_name="post_below_content"]

Ilika plc (LON:IKA) Chief Executive Officer Graeme Purdy caught up with DirectorsTalk for an exclusive interview to discuss their relationship with Cirtec, P1 cells milestone, regulatory outlook, further opportunities for grant support, and the key challenges in the coming year.

Q1: Cirtec, it’s featured prominently this year. How is the relationship progressing and what’s still to come?

A1: It’s a great relationship. Just to recap, of course, we entered into a 10-year licensing agreement with them last year and we transferred our pilot line production kit across to their facility in Lowell, Massachusetts.

They have now substantially completed the installation of that equipment and have demonstrated that they have commissioned it in a way that it needs to operate in order to make our Stereax batteries.

So there’ll be a bit of news flow later on in the summer confirming that installation, that everything’s ready to start making the engineering lots and as we get towards the end of the year, we will start production of our next M300s with a view to start sending them to customers in 2025.

Q2: How big a milestone is the delivery of P1 cells for Ilika?

A2: So, talking about Goliath now, the P1 cells, that’s really been the culmination of a fantastic avalanche of achievements from the team over the last six months or so.

Remember at the end of last year, we announced our D4 development milestone, which was a design freeze to allow us to manufacture and test a batch of our P1 prototype cells, which we successfully did. And actually there’s been two bits of news around that.

On the one hand, we’ve commenced a customer sponsored in-house test program. So, one of our customers has said, well Ilika, you guys have got all the test equipment you need to do this for us, we will sponsor you to do that testing at your own facility.

On the other hand, the most recent press release that we sent out was indeed the delivery of a batch of those P1 cells to a customer that’s paid for them and wants to actually test them in-house at their own facility.

So, that’s basically an indication that we’ve successfully validated that P1 prototype, and I think investors can take a lot of comfort from that.

Q3: Does the regulatory outlook still look positive?

A3: Yes, I think actually with the new government here in the UK, we’re going to see a bit of a resurgence of enthusiasm for the net zero agenda. I think the regulatory environment, both here in the UK and more broadly, is very conducive to EVs and the adoption of our Goliath technology.

Q4: Now, you mentioned that you expect to see further opportunities for grant support in the future. What can investors expect there?

A4: First of all, really a very strong vote of thanks for the support that we’ve had from the Faraday Battery Challenge and also the Advanced Propulsion Centre, who have been the sources of two significant grants for us.

On the one hand, with the FBC, we have had the HISTORY program, which has been running since Q1 of 2023, and is a two-year program so that’ll run until Q1 of 2025. That’s really enabled us to work together with some of the leading universities here in the UK, with also collaboration with the CPI, Centre for Process Innovation, and HSMI, a consultancy that’s allowed us to do a full life cycle analysis, as well as our silicon anode supply partner, Nexeon, and under the supervision, actually, of Fortescue, WAE, and BMW. That’s been really great in terms of supporting our Goliath program.

Secondly, of course, the more recent grant support that we’ve had to work together with UKBIC and MPAC in order to develop our assembly line. That’ll give us a great capability to be able to produce up to 1.5 megawatt hours of prototypes per year at our facility.

Looking forward, we’ve got a great scale-up story as we move forward through to the later development points, and then our P2 prototypes by the end of 2025. So, great support, really, from those grant bodies in order to get us to where we’ve got to now, and also looking forward.

Q5: Finally, what hurdles will Ilika contend with in the coming year, do you think?

A5: Well, I think key challenges for us will be to deliver on those Goliath development points. It’s not everybody in the world that can do this.

We have a unique value proposition in terms of the capabilities of our Goliath batteries, some great safety data coming out that we’ll talk about later on in this current calendar year, and we need to translate that into larger batteries.

Our P1 batteries are a two-amp-hour battery. We are gradually making bigger and bigger batteries that we’re sharing with our partners and we’ll need to incorporate their feedback and the test results that we get from that scale-up into our designs.

We’ve got very supportive shareholders and we’ve also got a lot of grant support that we’re just talking about. So, I think the augers are looking very positive at the moment.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
Ilika plc's CEO discusses a breakthrough in solid-state battery tech for EVs with successful testing of 10Ah cells in the Goliath project.
Ilika plc achieves a major milestone with its Goliath solid-state batteries, successfully testing 10Ah cells and advancing towards a market-ready MVP.
Ilika plc, a leader in solid-state battery tech, is poised for growth with key milestones in medical and automotive sectors targeted for 2025.
Ilika plc updates on its solid-state battery advances, focusing on Stereax for AIMDs and Goliath for EVs, maintaining its full-year guidance.

Search

Search